Aptevo Therapeutics Secures $60 Million Equity Line of Credit to Support Multispecific Portfolio Advancement, Increase Strategic Optionality
Rhea-AI Summary
Aptevo Therapeutics (NASDAQ: APVO) entered a $60 million equity line of credit with Yorkville Advisors to provide incremental, market-based capital access. Combined with cash on hand, the fully leveraged facility is stated to extend Aptevo's funding runway into 2029 to support clinical and preclinical multispecific oncology programs. Proceeds will fund ongoing clinical development, advance preclinical programs, and general corporate purposes. The company retains discretion to draw on the facility; terms note minimal fees and no warrants. Aptevo's pipeline includes five CD3-engaging assets led by mipletamig (CD123×CD3), evaluated in >100 patients with reported high remission rates and no observed cytokine release syndrome in frontline patients to date.
Positive
- $60M equity line increases near-term liquidity and strategic optionality
- Runway extended into 2029 when combined with cash on hand
- No warrants on the ELOC reduces typical dilutive features
- Mipletamig evaluated in >100 patients with reported high remission rates and no CRS in frontline patients
Negative
- Equity line dilutive if drawn and shares are sold into the market
- Capital access is at market-based conditions, which could result in unfavorable pricing when executed
News Market Reaction
On the day this news was published, APVO gained 5.00%, reflecting a notable positive market reaction. Argus tracked a peak move of +26.9% during that session. Argus tracked a trough of -24.5% from its starting point during tracking. Our momentum scanner triggered 21 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $410K to the company's valuation, bringing the market cap to $9M at that time. Trading volume was exceptionally heavy at 42.9x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
APVO is up 3.31% while key biotech peers (XBIO, GRI, OGEN, ONCO, QNRX) show negative moves between -0.68% and -7.19%, indicating a stock-specific reaction rather than a sector-wide move. Momentum scanner only flagged SXTP up 5.37% without news.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| 2025-12-26 | Reverse stock split | Negative | -34.7% | 1-for-18 reverse split reducing outstanding common shares to about 1 million. |
| 2025-12-09 | Clinical data update | Positive | -7.5% | ASH 2025 RAINIER data showing high remission and no CRS in frontline AML. |
| 2025-11-10 | Preclinical data | Positive | +6.1% | Debut of trispecific APVO451 with tumor-localized immune activation data. |
| 2025-11-06 | Earnings and update | Positive | +2.8% | 3Q25 results, strong remission data and cash runway guidance into 4Q26. |
| 2025-10-08 | Conference participation | Neutral | -2.8% | Announcement of multiple upcoming scientific and investor conference presentations. |
Recent positive clinical and business updates have often seen mixed or negative next-day price reactions, while capital structure actions like reverse splits have coincided with sharp declines.
Over the last few months, Aptevo has combined active clinical development with frequent capital markets activity. A 1-for-18 reverse split on 2025-12-26 preceded a -34.73% move. Strong mipletamig AML data at ASH 2025 still saw a -7.46% reaction, while preclinical trispecific APVO451 data on 2025-11-10 and 3Q25 earnings with runway into 4Q26 drew modest gains. The new $60 million ELOC continues this pattern of using equity-linked financing to extend runway for the multispecific portfolio.
Market Pulse Summary
The stock moved +5.0% in the session following this news. A strong positive reaction aligns with the company’s goal of extending runway to support its multispecific pipeline. The $60 million equity line, together with existing cash and prior Yorkville/ATM facilities, has historically been used to finance R&D. However, prior offerings and reverse splits have coincided with sharp drawdowns, and the stock trades 99.53% below its 52-week high, so dilution sensitivity and past volatility could still constrain sustainability.
Key Terms
equity line of credit financial
CD3 medical
bispecific medical
trispecific medical
cytokine release syndrome medical
Phase 1b/2 medical
AML medical
AI-generated analysis. Not financial advice.
Together with cash on hand, the fully leveraged facility extends Aptevo's funding runway into 2029, enabling achievement of key clinical and preclinical milestones
SEATTLE, WA / ACCESS Newswire / January 9, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology Company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR® and ADAPTIR-FLEX® platform technologies, today announced that the Company has entered into a
The facility provides Aptevo with access to capital, allowing the Company to raise funds incrementally, at its discretion, and under market-based conditions. Further, an ELOC offers affordable capital financing with minimal fees and no warrants. Proceeds from the ELOC will be used to support ongoing clinical development, advance preclinical programs, and fund general corporate purposes.
"This agreement offers added flexibility and control over how and when we access capital," said Daphne Taylor, Chief Financial Officer at Aptevo. "Importantly, the fully leveraged facility plus cash on hand is sufficient to fund us for three years, into 2029. During this time, we plan to continue generating clinical data and advancing differentiated assets across the portfolio focusing on execution and value creation."
The ELOC complements Aptevo's existing capital resources and is designed to support the Company's disciplined approach to balance sheet management, while preserving optionality around future strategic and growth decisions.
Under the terms of the agreement, Aptevo has the right, but not the obligation, to sell shares to the counterparty from time to time, subject to customary conditions and limitations. The Company is not required to draw on the facility and retains full discretion over its use.
Aptevo's portfolio includes five CD3-engaging assets anchored by mipletamig, a first-in-class CD123 x CD3 bispecific currently being evaluated in RAINIER, a Phase 1b/2 trial for frontline AML. In total, mipletamig has been evaluated in more than 100 patients across three trials, where mipletamig has consistently demonstrated high remission rates and a favorable safety and tolerability profile, with no observed events of cytokine release syndrome in frontline patients treated to date.
Building on this clinical validation, Aptevo has built a portfolio of tumor-directed CD3 programs, including bispecific candidates APVO442 (PSMA × CD3) for prostate cancer and APVO455 (Nectin-4 × CD3) for solid tumors, as well as trispecific candidates APVO451 and APVO452. All incorporate the Company's proprietary application and unique use of the CRIS-7-derived CD3 binding domain, designed to enable tumor-focused immune activation with the potential for meaningful antitumor activity while also prioritizing safety and tolerability.
About Aptevo Therapeutics
Aptevo Therapeutics Inc. (NASDAQ:APVO) is a clinical-stage biotechnology company focused on developing novel bispecific and trispecific immunotherapies for the treatment of cancer. The Company has two clinical candidates. Mipletamig is currently being evaluated in RAINIER, a two-part Phase 1b/2 trial for the treatment of frontline acute myeloid leukemia in combination with standard-of-care venetoclax + azacitidine. Mipletamig has received orphan drug designation ("orphan status") for AML according to the Orphan Drug Act. ALG.APV-527, a bispecific conditional 4-1BB agonist, designed to only be active upon simultaneous binding to 4-1BB and 5T4, is being co-developed with Alligator Bioscience and was most recently evaluated in a Phase 1 clinical trial for the treatment of multiple solid tumor types likely to express 5T4. The Company has six preclinical candidates with different mechanisms of action designed to target a range of solid tumors. All pipeline candidates were created from two proprietary platforms, ADAPTIRand ADAPTIR-FLEX. The Aptevo mission is to improve treatment outcomes and transform the lives of cancer patients. For more information, please visit www.aptevotherapeutics.com.
Safe Harbor Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, without limitation, Aptevo's expectations about the activity, efficacy, safety, tolerability and durability of its therapeutic candidates and potential use of any such candidates, including in combination with other drugs, as therapeutics for treatment of disease, its expectations regarding the effectiveness of its ADAPTIR and ADAPTIR-FLEX platforms, statements related to the progress of Aptevo's clinical programs, including statements related to anticipated clinical and regulatory milestones, whether further study of mipletamig in a Phase 1b dose optimization trial focusing on multiple doses of mipletamig in combination with venetoclax + azacitidine on a targeted patient population will continue to show remissions, whether Aptevo's final trial results will vary from its earlier assessment, whether Aptevo's strategy will translate into an improved overall survival in AML, especially among patient subgroups with poor prognosis, whether further study of ALG.APV-527 across multiple tumor types will continue to show clinical benefit, the possibility and timing of interim data readouts for ALG.APV-527, development and continued development of Aptevo's current and potential future molecules, statements related to Aptevo's cash position and balance sheet, statements related to Aptevo's ability to access to capital and funding runway, statements related to Aptevo's ability to generate stockholder value, whether Aptevo will continue to have momentum in its business in the future, and any other statements containing the words "may," "continue to," "believes," "knows," "expects," "optimism," "potential," "designed," "promising," "plans," "will" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on Aptevo's current intentions, beliefs, and expectations regarding future events. Aptevo cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from Aptevo's expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement.
There are several important factors that could cause Aptevo's actual results to differ materially from those indicated by such forward-looking statements, including Aptevo's need to obtain shareholder approval to access the full capacity of the ELOC, a deterioration in Aptevo's business or prospects; further assessment of preliminary or interim data or different results from later clinical trials; adverse events and unanticipated problems, adverse developments in clinical development, including unexpected safety issues observed during a clinical trial; and changes in regulatory, social, macroeconomic and political conditions. For instance, actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the uncertainties inherent in the results of preliminary or interim data and preclinical studies being predictive of the results of later-stage clinical trials, initiation, enrollment and maintenance of patients, and the completion of clinical trials, the availability and timing of data from ongoing clinical trials, the trial design includes combination therapies that may make it difficult to accurately ascertain the benefits of mipletamig, expectations for the timing and steps required in the regulatory review process, expectations for regulatory approvals, the impact of competitive products, our ability to enter into agreements with strategic partners or raise funds on acceptable terms or at all and other matters that could affect the availability or commercial potential of Aptevo's product candidates, business or economic disruptions due to catastrophes or other events, including natural disasters or public health crises, geopolitical risks, including the current war between Russia and Ukraine and any other military event that could evolve out of any of the current conflicts, and macroeconomic conditions such as economic uncertainty, imposition of tariffs, rising inflation and interest rates, continued market volatility and decreased consumer confidence. These risks are not exhaustive, Aptevo faces known and unknown risks. Additional risks and factors that may affect results are set forth in Aptevo's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and its subsequent reports on Form 10-Q and current reports on Form 8-K. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from Aptevo's expectations in any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, Aptevo does not assume any obligation to update any forward-looking statement to reflect new information, events, or circumstances.
CONTACT:
Miriam Weber Miller
Head, Investor Relations & Corporate Communications
Aptevo Therapeutics
Email: IR@apvo.com or Millerm@apvo.com
Phone: 206-859-6628
SOURCE: Aptevo Therapeutics
View the original press release on ACCESS Newswire
FAQ
What did Aptevo (APVO) announce on January 9, 2026 about new financing?
How long does the $60M equity facility plus cash fund Aptevo (APVO)?
Will the Yorkville equity line for APVO include warrants or large fees?
What clinical progress did Aptevo highlight for mipletamig (APVO)?
How might the APVO equity line affect shareholders?
